Understand Binhai Inv's 2025 Performance in One Chart.
In 2025, the total annual revenue reached 5.606 billion yuan; net profit attributable to shareholders reached 206 million yuan, a significant increase of 12% year-on-year; the company fulfilled its dividend policy commitment, intending to distribute dividends of 8.36 Hong Kong cents per share in 2025, a 10% increase year-on-year, and has consistently paid dividends for 13 consecutive years.
Recently, BINHAI INV (02886) released its performance for the year 2025. In 2025, the company's profitability achieved stable growth and the shareholder return capability continued to strengthen. The company achieved a total operating revenue of 5.606 billion RMB in 2025; net profit attributable to owners reached 206 million RMB, a significant year-on-year increase of 12%; the company fulfilled its dividend distribution policy commitment, planning to distribute a dividend of 8.36 Hong Kong cents per share in 2025, a 10% increase from the previous year, and has consistently distributed dividends for 13 consecutive years.
Related Articles
PepsiCo, Inc. localizes over 90% of its raw materials to strengthen hedging against risks from GEO Group Inc
HK Stock Market Move | Bitcoin has fallen by nearly 10% in the past month, LINEKONG (08267) has dropped more than 12%, and GOLDSTREAM INV (01328) has fallen by almost 11%.
Zhejiang Starry Pharmaceutical (603520.SH) plans to acquire a 20% stake in Rui Shi Pharmaceutical for 10 million yuan to increase CMO production capacity.
PepsiCo, Inc. localizes over 90% of its raw materials to strengthen hedging against risks from GEO Group Inc
HK Stock Market Move | Bitcoin has fallen by nearly 10% in the past month, LINEKONG (08267) has dropped more than 12%, and GOLDSTREAM INV (01328) has fallen by almost 11%.
Zhejiang Starry Pharmaceutical (603520.SH) plans to acquire a 20% stake in Rui Shi Pharmaceutical for 10 million yuan to increase CMO production capacity.
